Article

B&L launches Stellaris Vision Enhancement System

Bausch & Lomb (B&L) today launched its new Stellaris Vision Enhancement system, further demonstrating its dedication to its microincision cataract surgery franchise.

Bausch & Lomb (B&L) today launched its new Stellaris Vision Enhancement system, further demonstrating its dedication to its microincision cataract surgery franchise.

Following on from the successes of the Millennium Microsurgical System and the Akreos acrylic intraocular lenses (IOLs), Stellaris offers surgeons the opportunity to perform both biaxial and coaxial microincision cataract surgery (B-MICS and C-MICS, respectively) procedures through a 1.8 mm incision.

According to the firm, the Stellaris EQ fluidics management technology allows surgeons to choose either a flow-vacuum module (AFM) or an advanced vacuum module (AVM). It also allows them to switch between the two for greater flexibility, stability and efficiency.

Additional features include the new ergonomically-designed, six-crystal phaco handpiece, Bluetooth wireless-enabled dual-linear foot pedal, and high-definition touch-screen display.

"With the launch of the Stellaris Vision Enhancement System and our Akreos MI60 microincision lens, we are poised to further enhance our leadership position," said Alan Farnsworth, B&L corporate senior vice president and president, Europe, Middle East and Africa Region.

According to H. Burkhard Dick, MD of Universitäts-Augenklinik, Center for Vision Science, Ruhr University, Germany, who has used the Stellaris system in more than 50 cases, it offers good performance, control and versatility. Meanwhile, he feels the optimized cutting deals with even the hardest nuclei whilst the improved fluidics contribute greatly to chamber stability when performing both biaxial and microcoaxial phaco.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.